Table 2.
IMP3 signatures in cases and controls and IMP3 overexpression in serous tubal intraepithelial carcinoma and pelvic serous carcinoma
|
Group |
#case |
Mean |
IMP3 signatures |
STIC |
PSC |
|---|---|---|---|---|---|
| age | (Total#) | #of + cases/HR (%) | #of + cases (%) | ||
| LR |
196 |
48.6 |
25 |
0 (0) |
0 (0) |
| HR |
60 |
46.2 |
226 |
5/9 (55) |
0 (0) |
| PSC | 60 | 61.5 | 184 | 11/19 (58) | 38 (63) |
HR: high-risk; STIC: serous tubal intraepithelial carcinoma; PSC: pelvic serous carcinoma. The frequency of IMP3 signatures was much higher in tubal fimbria of patients with high-risk (9.04-fold) and those with PSC (7.36-fold) than that in control group (p < 0.0001).